- Home
- SUPN vs GENI Comparison
SUPN vs GENI Comparison
Compare SUPN & GENI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUPN | GENI |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | SUPN | GENI |
|---|---|---|
| Price | $49.74 | $11.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 17 |
| Target Price | ★ $61.60 | $14.47 |
| AVG Volume (30 Days) | 634.2K | ★ 4.5M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $681,539,000.00 | $604,524,000.00 |
| Revenue This Year | $8.32 | $30.85 |
| Revenue Next Year | $23.36 | $19.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.54 | ★ 30.70 |
| 52 Week Low | $29.16 | $8.15 |
| 52 Week High | $57.65 | $13.73 |
Technical Indicators
Market Signals| Indicator | SUPN | GENI |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 63.83 |
| Support Level | $51.01 | $10.59 |
| Resistance Level | $52.30 | $11.02 |
| Average True Range (ATR) | 1.40 | 0.30 |
| MACD | 0.35 | 0.06 |
| Stochastic Oscillator | 64.48 | 87.63 |
Price Performance
Historical ComparisonAbout SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.